Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AML Master Protocol For Precision Medicine Developed By Nonprofit And US FDA

Executive Summary

Leukemia & Lymphoma Society worked with US FDA on umbrella trial strategy to accelerate development of new targeted therapies in molecularly-defined subsets of AML.


Related Content

Master Protocols In Practice
Genentech Wants Other Firms' Compounds For Mass Pediatric Cancer Screening
FDA Hold On Seattle Genetics' Trials Clouds CD33's Suitability for AML
Biomarkers For Pancreatic Cancer To Be Tested In Multi-drug Collaborative Study
I-SPY 2 Helping To Normalize Adaptive Trial Designs
Genomics-Driven Trials Built To Be Fast And Flexible


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts